Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting.

Secondary Clinical and Laboratory Outcomes GH showed a trend toward improvement starting from W12 in both groups and becoming significant at W48 compared to baseline, with no significant differences in the two groups (RTX originator group W0: 33.3 ± 22.9, W48: 70 ± 17.89; p = 0.01; CT-P10 group W0: 30 ± 16, W48: 76.7 ± 11.5; p = 0.02) ( Figure 2 ).

also in 53,322 other papers